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according to the location of the drugstore and in accordance with the area of capacity 
in the workers of ANVISA. RESULTS: There were interviewed 105 consumers in 
drugstores and 140 workers of ANVISA. When asked about the existence of market 
regulation of drugs, 51.43% and 87.14% of drug users and employees of ANVISA, 
respectively, said there is regulation of these products. About the PMC, the knowledge 
was 20.00% of respondents in pharmacies and 57.86% of the employees of ANVISA. 
Despite of the relative knowledge of PMC, only 01 of the respondents knew where 
consumers search the PMC, and the employees of ANVISA, 29 knew the sources of 
research. Although the poor knowledge on the regulation of prices, 84.76% of con-
sumers interviewed considered this activity exerted by the government as important. 
CONCLUSIONS: Although the population consider important that the prices of 
medicines are regulated by the government, the knowledge of the regulation is small, 
even on the tools of consumer protection.
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OBJECTIVES: This study was investigating of costs and consequences of two manual 
and computerized systems for management of information during 2008–2009 for 
inspection of pharmaceutical industries in Iranian Drug Regulatory Affairs. 
METHODS: To compute costs of processes following items had been considered: Cost 
of ﬁ lling and archiving, data collecting (person-hour), reporting (person-hour), trans-
port, software, hardware (main server computer, pocket computer), stationeries. To 
evaluate the efﬁ cacy following outputs and outcomes was considered: Time of infor-
mation recovering, ability of ranking, preventing of data missing, capacity building 
and tracking and monitoring. RESULTS: The cost of running the new system is 35,000 
US Dollars. Cost of education in new method and conventional are 5000 and 1000 
US Dollars respectively. Cost of inspection in computerized management of informa-
tion system (MIS) is decreased to 250 US Dollars from 600 US Dollars for each 
inspection process. Alongside capacity of system is increased by arming to fast process-
ing method, time of information recovering diminished to 1 working day instead of 
3 days, preventing of data missing from 80% to 95% in new one, tracking and moni-
toring took 7 working days to applied, but new MIS changed that to 1 working day. 
Ranking of pharmaceutical industries is now available for Iranian Drug Regulatory 
Affairs after establishment of new inspection system by computer-based MIS. CON-
CLUSIONS: It seems that beside overhead cost of new computerized system that is 
more than conventional method; considering capacity building; due to decreasing the 
cost of inspection and increasing of outputs and outcomes indicators, the new system 
is more efﬁ cient.
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OBJECTIVES: Patients, health service providers, payers and the society also gain from 
intensive clinical trial participation, however the majority of beneﬁ ts are intangible. 
According to a recent survey Hungary generates 0.15% of the GDP from clinical trials 
and related activities, therefore the economic importance of this area is acknowledged 
by the Hungarian government. The clinical trial activity is traditionally strong in the 
country, however the growth rate of clinical trials is lower than in other Central-
Eastern European countries. Our objective was to explore how Hungary can improve 
its competitiveness in attracting clinical trials. METHODS: We conducted a literature 
review, searched for publicly available documents and interviewed key stakeholders 
in Hungary to explore potential ﬁ elds for intervention. RESULTS: We identiﬁ ed seven 
key target areas for intervention to improve the competitiveness of Hungary in clinical 
trials: the simpliﬁ cation of legal framework for clinical trial related activities, develop-
ment of infrastructure at main potential sites, organizational development with special 
focus on SMOs, the simpliﬁ cation of rules and processes for ﬁ nancing clinical trials, 
investment into developing databases to support the set-up of clinical trials, and ﬁ nally 
the marketing promotion of Hungary and its sites to sponsors of clinical trials. CON-
CLUSIONS: The area of international clinical trials is a very competitive market. 
Hungary can strengthen its market position, if legislators, competent authorities and 
management teams of investigational sites—by acknowledging the professional and 
ﬁ nancial beneﬁ ts of these studies—support the successful implementation of clinical 
trials in coordinated actions.
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OBJECTIVES: To analyze the effects of liberalization of regulations, concerning 
establishment of pharmacies and pharmacy points in Poland after 1989. METHODS: 
The data on the number of pharmacies and pharmacy points, used for the analysis were 
collected by mail survey completed by all regional pharmaceutical supervision authori-
ties. Population data were sourced from the statistical yearbook of Poland. RESULTS: 
During economic transition Poland was one of few European Union countries, where 
the number of pharmacies was not regulated within a given area. Therefore, their 
numbers increased rapidly, reaching 12.153 private pharmacies and 1.397 private 
pharmacy points in 2009. This means that in 2009 one pharmacy served 3.127 people. 
Before privatization process started in 1989, all retail pharmacies were managed by a 
state-owned enterprise “Cefarm”. Since then, the regulations have changed and the 
number of pharmacies started to grow. The main reasons of this trend was a regulation 
stipulating that permission to establish a pharmacy can be granted to any private or 
legal person, disregarding professional education of that person. Pharmacy owner was 
only required to employ a qualiﬁ ed pharmacist, responsible for managing the phar-
macy. Another major institutional change was introduced by the Pharmaceutical Law, 
voted October 10, 1991, which authorized establishment of pharmacy points. In spite 
of the general trend, in some poor provinces of Poland the number of pharmacies 
decreased. June 1, 2010, European Court of Justice ruled that the right to own and 
operate a pharmacy may be reserved exclusively for pharmacists and that demographic 
or geographic criteria may be used in the process of issuing permits to operate pharma-
cies. CONCLUSIONS: Currently, the Polish Ministry of Health has to propose 
amendments to the Pharmaceutical Law, implementing the above mentioned 
criteria.
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OBJECTIVES: To investigate changes realized in the Czech pricing and reimbursement 
system since January 2008 and to describe the current development of this system. 
METHODS: We described the legal framework deﬁ ning the Czech system (Act No. 
48/1997 Coll. as amended by the Act No. 261/2007 Coll. on Public Health Insurance) 
as well as evaluation of the current system from the literature and reports provided 
by the State Institute for Drug Control (SUKL). RESULTS: In order to increase trans-
parency according to EU Transparency Directive and to set fairly-deﬁ ned deadlines 
the competencies for the pricing and reimbursement system were merged from Min-
istries of Finances and Ministry of Health (MoH) under one responsible institution—
SUKL. The pricing rules were fully changed—the maximum price is set based as the 
mean value of all available ex-factory prices in the reference countries (Estonia, France, 
Italy, Lithuania, Hungary, Portugal, Greece and Spain). The reference reimbursement 
system contains 251 reference groups of therapeutically interchangeable products with 
similar clinical efﬁ cacy and safety (should be updated annually by MoH). Medicinal 
products included in one reference group have the main common therapeutic indica-
tion in the same reimbursement level which is calculated on the basis of retail prices 
in all EU countries. The cheapest price for equipotent dose is chosen and re-counted 
according to local pharmacy and wholesaler margins and value added taxes. In compli-
ance with new legislation the pharmacoeconomic criteria (cost-effectiveness evaluation 
and budget impact analysis) should be taken into account. There is possibility of extra 
bonus of basic reimbursement for better efﬁ cacy, safety, dosing schedule, compliance, 
etc. CONCLUSIONS: The system has gone through dramatic changes in last two years 
and some aspects are still facing challenges. Although the new system should reassessed 
all medicines covered in the country till 2008, currently there are only 20% revised 
(April 2010). 
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OBJECTIVES: Whilst patient access schemes (PAS) are not a new concept, they are 
clearly receiving increasing attention. The ﬁ rst notable PAS, devised to improve access 
to beta interferons for multiple sclerosis, was an outcomes-based scheme designed to 
overcome uncertainty in long-term clinical and cost-effectiveness. It is the nature of 
the uncertainty that drives the design of PAS, but is there a trend towards which 
schemes are more popular? We analyzed the design of published PAS employed in the 
UK in order to determine if outcomes-based or ﬁ nancial-based schemes predominate. 
METHODS: Published PAS were identiﬁ ed from health technology assessment web-
sites (e.g. the National Institute for Health and Clinical Excellence and Scottish Medi-
cines Consortium), literature searching of ISPOR conference abstracts, and searching 
of ‘patient access scheme’ or ‘risk-sharing scheme,’ using internet search engines. PAS 
identiﬁ ed were categorised as ﬁ nancial-based (price- or volume-based agreements) or 
outcomes-based schemes. Desk research was the performed to identify the preference 
for each type of scheme, in terms of uptake by UK Primary Care Trusts. RESULTS: 
Seventeen published PAS were identiﬁ ed from the literature search, from 2002 until 
2010. Categorization of PAS as ﬁ nancial-based versus outcomes-based showed that 
schemes were balanced, but favoured ﬁ nancial-based schemes (59% versus 41%, 
respectively). The uptake of ﬁ nancial-based schemes was found to be higher than 
outcomes-based schemes due to administrative burden posed by schemes which rely 
